From: Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
Study | Year | Country | Total (N = 388) | Study Characteristics | Tx A (n) | Tx B (n) | Aspirin dose per day | |
---|---|---|---|---|---|---|---|---|
Study Design | Randomization | |||||||
Son et al. | 2011 | US | 106 | Retrospective | N/A | IVIg (86) | IFX (20) | 80-100 mg/kg until afebrile then 3-5 mg/kg |
Youn et al. | 2016 | Korea | 43 | Prospective | + | IVIg (32) | IFX (11) | 80-100 mg/kg until afebrile |
Teraguchi et al. | 2013 | Japan | 41 | Prospective | + | IVIg (27) | IVMP (14) | 30 mg/kg |
Furukawa et al. | 2008 | Japan | 63 | Prospective | – | IVIg (19) | IVMP (44) | 30 mg/kg tapered to 10 mg/kg then 5 mg/kg |
Ogata et al. | 2008 | Japan | 27 | Retrospective | N/A | IVIg (14) | IVMP (13) | 80-100 mg/kg |
Miura et al. | 2005 | Japan | 22 | Prospective | + | IVIg (11) | IVMP (11) | |
Miura et al. | 2011 | Japan | 74 | Prospective | – | IVIg (74) | – | 30 mg/kg until afebrile then 5 mg/kg until 8 weeks |
Singh et al. | 2015 | India | 12 | Retrospective | N/A | IFX (12) | – | 30 mg/kg until afebrile then 3–5 mg/kg |